NCT/Study#
NA /
2021-0704
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma
DISEASE GROUP:
Multiple Myeloma
current phase:
NA
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
